David Brandes
Neurology · Knoxville, TNNPI 1487761144
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $309,172 of the $412,138 with a category attached, or 75.0%. 33 manufacturers reported payments, led by Biogen at 41.3% of the total. Reporting peaked in 2019 at $223,919 and has fallen 100.0% since, to $43 in 2025. Among neurology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 581 payments — averaging $709.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$170K
- Novartis$49K
- Sanofi$48K
- AbbVie$37K
- Genentech USA, Inc.$35K
- Bristol Myers Squibb$24K
- plus $50K from 27 others
Across 11 payments — averaging $752.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$6K
- Sanofi$3K
What the payments were for
- Consulting fees$51,60713%
- Speaking & faculty fees$309,17275%
- Travel & lodging$39,0969%
- Food & beverage$12,2153%
- Education$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 146 | $170,118 |
| Novartis | 88 | $48,505 |
| Sanofi | 58 | $47,666 |
| AbbVie(2 entities) | 46 | $36,605 |
| Genentech USA, Inc. | 47 | $35,235 |
| Bristol Myers Squibb | 37 | $23,825 |
| Mallinckrodt Enterprises LLC | 10 | $14,609 |
| EMD Serono, Inc. | 26 | $12,859 |
| Amgen(2 entities) | 14 | $8,131 |
| Mallinckrodt Hospital Products Inc. | 6 | $8,003 |
| E.r. Squibb & Sons, L.L.C. | 15 | $4,235 |
| AstraZeneca | 10 | $405 |
| Johnson & Johnson | 13 | $374 |
| Avanir Pharmaceuticals, Inc. | 20 | $366 |
| Biohaven Pharmaceuticals, Inc. | 10 | $281 |
| Teva Pharmaceuticals USA, Inc. | 9 | $155 |
| Eisai Inc. | 1 | $125 |
| TG Therapeutics, Inc. | 2 | $116 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $99 |
| Genentech, Inc. | 2 | $93 |
| Banner Life Sciences, LLC | 4 | $81 |
| ANI Pharmaceuticals, Inc. | 2 | $41 |
| Jazz Pharmaceuticals Inc. | 2 | $33 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| Neurelis, Inc. | 1 | $24 |
| Catalyst Pharmaceuticals, Inc. | 1 | $24 |
| Cycle Pharmaceuticals Inc | 1 | $17 |
| Acorda Therapeutics, Inc | 1 | $17 |
| CSL Behring | 1 | $17 |
| Medtronic | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$412,138 in reported general payments places this provider in the 95th percentile of 361 neurology providers in Tennessee.
Other neurology in Knoxville
- Sibyl WrayKnoxville$377K
- Joseph VaughanKnoxville$177K
- Rosanne BarkerKnoxville$40K
- Randall TrudellKnoxville$39K
- Michelle BrewerKnoxville$37K
- Samuel HunterSpring Hill$676K
- Harold MosesNashville$438K
- Lucas ElijovichMemphis$415K
- Christine HagenAlcoa$371K
- Mark LedouxMemphis$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.